Article Text

Download PDFPDF

  1. Mark Willis,
  2. Katharine Harding,
  3. Mark Wardle,
  4. Trevor Pickersgill,
  5. Valentina Tomassini,
  6. Neil Robertson
  1. Institute of Psychological Medicine & Clinical Neuroscience, Cardiff University


Introduction Alemtuzumab is an anti-CD52 monoclonal antibody, approved for the treatment of relapsing multiple sclerosis (RMS). However, it has significant side effects and long-term follow-up is required to provide accurate information for patient management and counselling.

Methods Patients were followed prospectively within an active surveillance program and standardised data collected on a regional database. Data on patient demographics, adverse events, disability trajectories (EDSS), relapses and retreatment intervals were analysed.

Results 96 patients with highly active RMS were identified (69F:27M). Mean follow-up post treatment was 5.1 years. Most patients received 2 annual cycles but 27 (28.1%) received 3, 7(7.3%) received 4 and 2 (2.1%) received 5. Pre- and post-treatment annualised relapse rates were 2.1 and 0.4 respectively. Mean change in EDSS from baseline was 0.44. 8 patients developed secondary progression a mean of 2.8 years post treatment. A range of autoimmune disorders (AID), notably thyroid disease was identified in 45 (47%).

Discussion Our data supports the effectiveness of alemtuzumab in patients with RMS in reducing relapse rates. However, despite a paucity of inflammatory disease activity, disability accumulation continued in some patients. Overall retreatment rate was 37.5% and AID, whilst common, could be effectively identified through routine surveillance processes and managed without serious consequence.


Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.